Article page



Full Text:


Аbout 30-40 % of the world’s population suffer from various allergological diseases, which are based on a specific reaction of the body (hypersensitivity) to allergens. For the diagnosis and treatment of allergic diseases, allergen preparations are used. Initially, allergen preparations were obtained only from natural sources-plant pollen, animal hair (epithelium), domestic dust, food, etc. Now more than a few hundred protein allergen sequences are known, which made it possible to create a large number of recombinant allergen proteins. Recombinant allergens are used as novel products in allergodiagnosis and immunotherapy of allergic diseases. The use of recombinant allergens in diagnostic kits based on immunoassay methods such as ELISA or REAST, as well as in molecular diagnostics, is widely used. The first recombinant products has appeared over 15 years ago. Clinical studies showed that therapeutic efficacy of these drugs is not inferior to commercial, but studies assessing the efficacy and safety of Allergology based on recombinant proteins is still not finished. Recombinant allergens are recommended as standards for the determination of allergenic activity and for the standardization and validation of ELISA-based methods. The results of research conducted using recombinant allergens have expanded our knowledge of the structure and properties of allergens, allowed to create a classification based on their structural homology and cross reactivity.

Для цитирования:

For citation:


  • Refbacks are not listed

Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 3.0 License.

ISSN: (Print)
ISSN: (Online)